Nebivolol: A Different Beta-Blocker for Hypertension
Journal
Journal of Cardiology & Current Research
Date Issued
2016-04
Author(s)
Otljanska, M
Otljanski, A
DOI
10.15406/jccr.2016.05.00171
Abstract
Beta blockers are one of the classes of antihypertensive drugs, but there
are controversies of their use as an initial therapy in treatment of arterial
hypertension based on different guidelines for treatment of arterial hypertension.
Nebivolol is a third generation, highly selective β-adrenoceptor antagonist with
antihypertensive efficacy similar to other beta blockers but with unique function
of increasing the release of nitric oxide (NO) via activation of β3-adrenergic
receptors which improves endothelial function, produces vasodilatation,
improves arterial compliance and reduces peripheral vascular resistance.
Nebivolol highly selective lipophilic B1-adrenergic receptor antagonist and B3
agonist has different pharmacokinetics and pharmacodynamics profile from
other beta blockers with more favourable metabolic and hemodynamic profile,
like side effect profile, beta receptors blockade affinity, vasodilating properties,
and improvement of endothelial function. Nebivolol has been show to be
effective beta blocker for treatment of mild to moderate arterial hypertension as
monotherapy or in combination therapy.
are controversies of their use as an initial therapy in treatment of arterial
hypertension based on different guidelines for treatment of arterial hypertension.
Nebivolol is a third generation, highly selective β-adrenoceptor antagonist with
antihypertensive efficacy similar to other beta blockers but with unique function
of increasing the release of nitric oxide (NO) via activation of β3-adrenergic
receptors which improves endothelial function, produces vasodilatation,
improves arterial compliance and reduces peripheral vascular resistance.
Nebivolol highly selective lipophilic B1-adrenergic receptor antagonist and B3
agonist has different pharmacokinetics and pharmacodynamics profile from
other beta blockers with more favourable metabolic and hemodynamic profile,
like side effect profile, beta receptors blockade affinity, vasodilating properties,
and improvement of endothelial function. Nebivolol has been show to be
effective beta blocker for treatment of mild to moderate arterial hypertension as
monotherapy or in combination therapy.